Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Endobiliary radiofrequency ablation (RFA) with biliary stent has been reported to be a
beneficial treatment option for palliation of malignant biliary strictures. RFA uses a
high-frequency alternating current to generate heat and achieve coagulative necrosis when in
contact with tissue. Within the bile duct, RFA appears to be safe and may result in decreased
tumor ingrowth. However, most of therapeutic effects were expected to delay bile duct
obstruction rather than to decrease the tumor. Recently orally available chemotherapeutic
agent, S-1, an oral fluoropyrimidine, was reported as effective in patients with bile duct
adenocarcinoma. To date, little is known about the role of the addition of systemic
chemotherapy to RFA for cholangiocarcinoma. The aim of this study is to evaluate the combined
effect of RFA and S-1 in patients with unresectable cholangiocarcinoma.